Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel QT study in mCRPC
NCT01549951Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- May 2012
- Primary completion
- Jan 2015
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orteronel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Millennium Pharmaceuticals. Primary endpoint: Maximum Change From Baseline in QTc Interval Based on the Fridericia Correction Method. Started May 2012; status: completed.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01549951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01549951.